News

Tirzepatide Heart Benefits: Who the Label Covers

Creator: Nadia Okonjo, Health Writer
Published: 2026-09-07

In August 2026 the brand-name version of tirzepatide gained a new use on its label: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes. Here is what that covers, and what it doesn't.

Nadia Okonjo, Health Writer September 7, 2026 6 min read

A man in a navy long-sleeve jacket and full-length grey trousers walks along a wide gravel path toward the camera, low hills behind him

The short version

On August 27, 2026 the FDA signed off on a new use for the brand-name type 2 diabetes version of tirzepatide: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes who are already at high risk. The label is dated 08/2026.
The trial behind it, SURPASS-CVOT, ran tirzepatide against another working injection rather than a dummy one. Events happened in 12.2% on tirzepatide and 13.1% on the comparator over about four years — non-inferior, and the label states superiority was not established.
The new wording covers the type 2 diabetes product only. As of September 6, 2026, the weight and sleep-apnea version of tirzepatide lists no heart use at all.
For people with obesity and no diabetes, the measured cardiovascular finding so far is blood pressure: 24-hour readings ran 7.4 to 10.6 points below placebo at 36 weeks in a SURMOUNT-1 substudy with 494 usable 24-hour readings.
Compounded tirzepatide is different from an FDA-approved product: the formulation offered here is not FDA-approved and carries no cardiovascular indication.
SURMOUNT-MMO, a 15,374-person trial in adults with obesity and no diabetes, is expected to complete in October 2027 and is the study that will answer the question this one could not.

Here's the plain version. Tirzepatide heart benefits now have a formal place on the brand-name label, and the wording is narrower than the headlines made it sound. On August 27, 2026, the FDA signed a letter adding a new use for Mounjaro: lowering the risk of a heart attack, a stroke, or death from heart disease in adults who have type 2 diabetes and are already at high risk of those events. It came out of a trial that followed 13,299 people for about four years. If you don't have type 2 diabetes, that new wording isn't about you.

What actually happened

The trial is called SURPASS-CVOT. Everyone in it had type 2 diabetes plus heart disease they already knew about — about two thirds had coronary artery disease, and just under half had already had a heart attack. Half of them were given tirzepatide once a week. The other half were given dulaglutide, an older weekly injection that already had heart evidence behind it.

That matters, because most big drug trials compare a medicine against a placebo, a dummy injection with nothing in it. This one didn't. It set tirzepatide against a working medicine, which is a harder test and a different question.

Over a median of about four years — 210.1 weeks, in the label's own accounting — a first heart attack, stroke or cardiac death happened in 801 people on tirzepatide and 862 on dulaglutide. As percentages, 12.2% against 13.1%. The summary number was a hazard ratio of 0.92, and the range around it ran from 17% fewer events to 1% more (Nicholls and colleagues, New England Journal of Medicine, 2025).

As of September 6, 2026, the day this article was written, the Mounjaro prescribing information is dated 08/2026 and lists the heart wording under its recent major changes (prescribing information). The letter FDA sent to the manufacturer is signed the evening of August 27, 2026, and names that trial as the reason for the change.

"Non-inferior" is the phrase doing the work

This is the part worth slowing down for, because it decides what the result actually means.

Non-inferior means not meaningfully worse. It does not mean better. The trial was built around a modest question — does tirzepatide look after the heart at least as well as a medicine that already had that evidence? — and the answer was yes. The label says so directly: superiority to dulaglutide was not established.

So here is the honest sentence. In adults with type 2 diabetes and existing heart disease, tirzepatide matched an established medicine over four years, while lowering blood sugar and body weight more than it did. That is a real result. It is not a claim that tirzepatide is the strongest heart medicine on the shelf, and the trial never set out to show that.

What tirzepatide heart benefits mean if you take it for weight

Short answer: the new wording doesn't reach you.

Two different branded products contain tirzepatide. Mounjaro is the type 2 diabetes one, and it is the one that gained the heart indication. Zepbound is the weight and sleep-apnea one. As of September 6, 2026, the day this article was written, Zepbound's prescribing information — also revised 08/2026 — lists two uses only: long-term weight reduction, and moderate-to-severe obstructive sleep apnea in adults with obesity. Nothing about the heart.

That gap isn't a statement about biology. It's a statement about who was enrolled. The trial studied people with diabetes and known heart disease, so that is the group the label is allowed to describe.

Semaglutide makes a useful contrast, because the same question was asked a different way. In a trial called SELECT, 17,604 adults who had heart disease and carried extra weight, but did not have diabetes, were given either semaglutide or a placebo. Heart attacks, strokes and cardiac deaths happened in 6.5% on semaglutide and 8.0% on placebo (Lincoff and colleagues, New England Journal of Medicine, 2023). Against a dummy injection, in people without diabetes — a different design answering a different question, and the reason the brand-name semaglutide product for weight carries heart wording that doesn't mention diabetes at all. If you're weighing the two molecules in general rather than for the heart, tirzepatide versus semaglutide walks through the rest.

Two more findings, at two different levels of confidence

Researchers later went back to the same trial data and counted a wider set of events: deaths from any cause, heart attacks, strokes, stents and bypasses, hospital stays for heart failure, and kidney problems, all pooled together. That broader tally landed at 23.7% on tirzepatide against 27.4% on dulaglutide (Nissen and colleagues, JAMA Cardiology, 2026). Interesting, with the caveat the authors state themselves — this count was planned after the results were already in, which makes it a lead worth following rather than a settled answer.

The second finding is blood pressure, and it does involve people without diabetes. In a substudy of the weight-loss trial SURMOUNT-1, adults with obesity and no diabetes wore a cuff that took readings around the clock; 494 of them had usable readings at both the start and week 36. By that point their average 24-hour top number sat between 7.4 and 10.6 points below placebo, depending on the dose (de Lemos and colleagues, Hypertension, 2024).

That is a risk factor moving in a helpful direction. It is not the same thing as counted heart attacks, and it shouldn't be read as though it were. For the wider picture across weight, blood sugar, sleep apnea and the rest, what the tirzepatide trials show takes each one separately.

Where a compounded prescription sits in all this

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved, and it carries no cardiovascular indication of any kind. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. What compounded tirzepatide actually is explains how that works.

None of that settles whether treatment is right for a given person. A licensed provider may still prescribe a compounded formulation when they judge it appropriate, and that decision is between you and the doctor who reads your history. A licensed provider reviews every request, and not everyone qualifies.

If you already take tirzepatide and you have type 2 diabetes and heart disease, the sensible move isn't to change anything on the strength of a news item. It's to bring it up at your next check-in. Tirzepatide for type 2 diabetes covers what that conversation usually includes.

What to watch next

One trial will answer the question this one couldn't. SURMOUNT-MMO enrolled 15,374 adults with obesity and no diabetes, to see whether tirzepatide changes how often heart attacks, strokes and cardiac deaths actually happen. As of September 6, 2026, the day this article was written, its ClinicalTrials.gov record lists the study as active and no longer recruiting, with primary completion expected in October 2027.

Until that reads out, the narrow position is the honest one. A measured result in adults with diabetes and heart disease. A blood-pressure signal in people without diabetes. And an open question sitting in the middle.

Common questions

Do tirzepatide heart benefits apply to everyone taking it?

No. The new label wording covers adults who have type 2 diabetes and are at high risk of a heart attack or stroke, because that is who the trial enrolled. People taking tirzepatide for weight, and people without diabetes, were not studied in that trial, so nothing on the label speaks to them yet. A large trial in that second group is still running.

What does "non-inferior" actually mean?

It means not meaningfully worse than the drug it was compared with. SURPASS-CVOT was designed to test whether tirzepatide performed at least as well as dulaglutide on heart outcomes, an older weekly injection with existing heart evidence. It cleared that bar. The label states plainly that superiority to dulaglutide was not established, so the result is a match, not a win.

Is compounded tirzepatide approved to reduce heart risk?

No. FDA-approved versions of tirzepatide exist, but the compounded formulation offered here is not FDA-approved and carries no cardiovascular indication of any kind. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider may still prescribe a compounded formulation when they judge it appropriate.

Does the weight-loss version of tirzepatide have a heart indication?

Not as of September 6, 2026. The brand-name product prescribed for weight and for obstructive sleep apnea lists exactly those two uses on its current prescribing information, which was revised in 08/2026. The heart wording sits on the type 2 diabetes product instead, because that is the population the outcomes trial studied.

How does this compare with semaglutide's heart evidence?

Different design, different question. The SELECT trial gave 17,604 adults with heart disease and extra weight, but no diabetes, either semaglutide or a placebo; heart attacks, strokes and cardiac deaths occurred in 6.5% against 8.0%. That was a placebo comparison in people without diabetes. SURPASS-CVOT was a head-to-head against another working medicine in people with diabetes.

Should I start or switch to tirzepatide because of this?

That is a conversation with a prescriber, not something a label decides. A label describes a group that was studied; it does not say what suits your history, your other medicines or your risk profile. If you already take tirzepatide, bringing the news to your next check-in is more useful than changing anything on your own.